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Abstract Invasive fungal diseases (IFDs) have been widely
studied in recent years, largely because of the increasing
population at risk. Aspergillus and Candida species remain
the most common causes of IFDs, but other fungi are emerg-
ing. The early and accurate diagnosis of IFD is critical to
outcome and the optimisation of treatment. Rapid diagnostic
methods and new antifungal therapies have advanced disease
management in recent years. Strategies for the prevention and
treatment of IFDs include prophylaxis, and empirical and
pre-emptive therapy. Here, we review the available primary
literature on the clinical and economic burden of IFDs in
Europe from 2000 to early 2011, with a focus on the value
and outcomes of different approaches.
Introduction
Opportunistic invasive fungal diseases (IFDs) are a significant
cause of morbidity and mortality in immunocompromised
patients, and are associated with increased healthcare costs
[1].
Early diagnostics can improve treatment outcomes and
potentially reduce IFD-associated costs. Microscopy and his-
tology are practical and inexpensivemethods for IFD detection,
but cannot identify organisms to the species level and are often
invasive. Non-invasive methods include techniques to detect
fungal antigens (e.g. galactomannan, mannan, β-D-glucan) or
fungus-specific nucleic acids [polymerase chain reaction
(PCR)], or rely on specific radiological and clinical signs.
IFDs can be classified as possible, probable or proven based
on host, clinical and microbiological features using the
European Organization for Research and Treatment of
Cancer/Mycoses Study Group (EORTC/MSG) criteria [2].
In addition to the antifungal treatment of confirmed dis-
eases, approaches include prophylaxis, empirical therapy and
pre-emptive/diagnostic-driven therapy. Prophylaxis is recom-
mended for the prevention of infection in high-risk patients
[3–6]. Empirical therapy is an early approach in patients with
persistently febrile neutropaenia unresponsive to antibiotic
therapy. Pre-emptive/diagnostic-driven therapy is usually
based on the presence of specific clinical signs and fungal
biomarkers, but there is no consensus on the definition and
there may be overlap with empirical and targeted therapy
(Fig. 1) [7, 8].
Polyenes, azoles and echinocandins are used to treat IFDs.
These agents demonstrate high levels of antifungal activity,
although resistance is reported for all classes. Antifungal
treatment can be hampered by toxicity, poor tolerability or a
narrow activity spectrum, and limitations have driven efforts
to determine the efficacy of combination therapy, but no
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optimal treatment strategy has been identified [9]. The
Infectious Diseases Society of America (IDSA) currently
recommends fluconazole or an echinocandin as the first-
line therapy for candidiasis in non-neutropaenic patients;
for neutropaenic patients, initial therapy with echinocandins
is preferred until the Candida species is identified [10].
Voriconazole is the recommended therapy for invasive asper-
gillosis (IA) [11–13].
The aim of this article is to review the primary evidence on
the clinical and economic burden of IFDs in Europe,
encompassing the value and treatment outcomes of different
diagnostic and therapeutic approaches to management.
Methods
A strategic literature review was conducted to understand
the clinical burden of IFD in terms of epidemiology, out-
comes and treatment trends, and the economic burden of
IFD contributing to overall healthcare resource utilisation
(HCRU), including hospitalisations, length of stay (LOS) in
hospital, diagnostic procedures and additional treatment and
medications.
Literature search
PubMed/MEDLINE and EMBASE were searched to identify
the primary literature on IFDs (Supplementary Table 1).
Searches were limited to results published in English; during
the last 10 years (2000 to early 2011); and having reported
on human subjects. Abstracts from clinical congresses
[International Society for Pharmacoeconomics and
Outcomes Research (ISPOR), Interscience Conference on
Antimicrobial Agents and Chemotherapy (ICAAC), IDSA
and the European Society of Clinical Microbiology and
Infectious Diseases (ECCMID)] were searched for data that
may still have been in press. Abstract searches were limited to
results published in English; during the last 5 years (2005 to
2010); and having reported on human subjects. Key review
papers and reports issued by disease surveillance agencies
were utilised to define targeted searches.
Study eligibility and selection criteria
Available abstracts, full-text articles and other materials were
reviewed for inclusion using the criteria in Supplementary
Table 2.
Results
Literature analysis
In total, 224 primary literature articles and 194 clinical ab-
stracts were identified. After eligibility criteria were applied,
113 primary literature articles and 55 clinical abstracts were
reviewed. Bibliographies were screened, which identified 12
primary literature articles. The final literature field consisted
of 57 primary literature articles and 18 clinical abstracts
(Fig. 2) [14–88]. Two additional posters from Slovakia
Fig. 1 Variable definitions of
treatment strategies and relative
positions within the treatment
continuum
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were later provided by the sponsor and included in the
analysis [89, 90].
Clinical burden: mortality
IFD-related mortality
Twenty-one studies were identified across ten countries, in-
cluding one European-wide study, which explicitly reported
IFD-related or attributable mortality. However, a clear defini-
tion of IFD-related death was lacking in many studies, with
criteria ranging from all deaths during the study to patients
with hyphal invasion on autopsy. Many patients had underly-
ing conditions; differentiating mortality related to these con-
ditions from deaths directly caused by IFD was problematic.
Furthermore, the proportion of IFD-attributable deaths was
calculated using a variety of methods (e.g. in relation to the
total number of deaths or in relation to the total population).
Supplementary Table 3 reports the rates of IFD-related mor-
tality and risk factors by European country.
Overall mortality
The overall 28- or 30-day mortality burden in patients with
IFDs ranged from 1.5 to 82.4 %, with most estimates falling
between 35 and 45 %. Three studies fell outside this range,
with mortality estimates of <30 and >45 % [20, 33, 39]. These
mortality rates may be explained by specific patient popula-
tions, with the highest 28-day mortality rates (66.7–82.4 %) in
patients in an intensive care unit (ICU) with probable or
proven IA [20].
The 12-week overall mortality ranged from 22 to 47% [15,
19, 33, 51, 61]. Other time frames for mortality measures were
7, 14, 42, 60 and 100 days, 4 months and 4 years, and
Fig. 2 Flow diagram for literature identification
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mortality estimates ranged from 5 % in haematopoietic stem
cell transplant (HSCT) patients (at 100 days) [82] to 70.6% (at
14 days) in an ICU population with IA [20]. Twenty-one
studies reported mortality over an unspecified time frame.
The highest overall mortality rate (90 %) was reported in
paediatric patients with haematological malignancies and IA
[76], and in ICU patients withCandida non-albicans infection
[45].
The overall mortality due to Candida infection ranged
from 20 to 90 %; however, after the exclusion of ICU popu-
lations, this narrowed to 20–32%. In a study byAlmirante and
colleagues, the rates of overall mortality of 23 and 43 % were
reported for patients with C . parapsilosis and C . albicans ,
respectively (p =0.003) [64].
The overall mortality range for Aspergillus infections was
30–90 %, and remained high, irrespective of whether known
ICU populations were excluded.
These results indicate that mortality rates in patients receiv-
ing antifungal treatment depend on the time period over which
mortality is measured, the responsible organism and the un-
derlying disease characteristics of the patient.
Diagnosis of IFD
Antigen-based assays
Galactomannan testing for the diagnosis of Aspergillus
infections was reported in 20 studies across ten countries.
All of the studies used serum specimens, and three also
used bronchoalveolar lavage (BAL) fluid [15, 22, 61]. BAL
testing was preferred in the study by Slobbe and colleagues
[61], and serum was only used when a bronchoscopy could
not be performed. The testing frequency ranged from twice
weekly [28, 78, 79] to daily monitoring [17] as part of a
screening strategy. Four studies measured galactomannan
following a triggering event as part of an intensive diag-
nostic workup (IDWU) [18, 51, 57, 61]. Optical density
cut-offs ranged from >0.5 to ≥1.5; the most frequently used
criteria for positivity was an optical density index ≥0.5 for
two consecutive tests.
Reports varied regarding the utility of galactomannan test-
ing in the diagnosis of IFD. Barnes and colleagues investigat-
ed the use of a febrile neutropaenia care pathway that used
routine biomarker testing in patients with acute leukaemia,
refractory disease undergoing aggressive chemotherapy or
undergoing HSCT [79]. In this study, 61 patients were posi-
tive for Aspergillus by PCR; of these, 25 (41 %) were positive
using the galactomannan assay. Thirty-two patients were pos-
itive by galactomannan testing and all but seven were also
positive by PCR. Thirty-six patients were positive by
Aspergillus PCR alone. Antigen testing (galactomannan and
mannan) was less sensitive than PCR but demonstrated good
specificity. Combined antigen and PCR testing gave a
sensitivity of 100 and 87.5 % for single and multiple results,
respectively, and a specificity of 100 %.
Girmenia and colleagues used galactomannan testing as
part of an IDWU and reported detection in 89 % of cases
[51]. Galactomannan assays contributed to diagnosis in 26
of 100 IDWU as a result of at least two positive samples,
while 42 of 100 IDWU computed tomography (CT) find-
ings led to IFD diagnosis. Both galactomannan tests and
high-resolution CT (HRCT) scans were positive in the
same IDWU in 74 % of patients who were diagnosed with
pulmonary IFD. The detection of galactomannan occurred
after a mean of 4.7 days (range 3–7 days) following the CT
results in four cases, and galactomannan test results were
negative despite positive culture findings in three cases
[51]. No further data regarding the specificity or sensitivity
were provided.
Mannan testing for the diagnosis of Candida infections
was reported in two studies, each using a minimum cut-off of
0.5 ng/ml [56, 79]. In the aforementioned study by Barnes and
colleagues [79], testing was performed twice weekly in con-
junction with other biomarker tests. Eleven patients had pos-
itive Candida PCR results, five of whom also had a positive
mannan antigen assay.
Posteraro and colleagues reported success with the use of
Candida mannan screening versus Candida culture surveil-
lance in BAL in the neonatal ICU [56]. Sixteen infants with
positive mannan assays were compared with 16 historical
controls with positive surveillance cultures. The incidence of
IFD in the surveillance culture group was 23 %; no cases of
IFDwere reported in the group undergoingmannan screening.
β-D-glucan is not specific for Aspergillus species and was
only referred to in a nationwide Aspergillus registry in Austria,
in which (1,3)β-D-glucan testing was used in 3 % of cases as a
diagnostic tool [15].
PCR-based testing
Studies conducted in the UK and Austria reported that PCR
testing was routinely performed in 4 and 16 % of cases,
respectively [15, 41]. PCR assays were used in a variety of
ways in addition to screening/pre-emptive strategies. For ex-
ample, in a study conducted in Germany, a positive PCR assay
of BAL specimens was used in conjunction with suspicious
CT findings for infection diagnosis [38]. By contrast, Rubio
and colleagues performed PCR testing as a confirmation assay
in patients who were positive for invasive filamentous fungal
infection by pathology [76].
A prospective study conducted in Germany compared out-
comes in patients following allogeneic HSCTwho were treat-
ed empirically with antifungals versus those treated pre-
emptively after PCR testing [39]. Patients treated with anti-
fungals after a positive PCR assay had significantly decreased
mortality at 30 days (p =0.015), but this survival benefit did
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not persist at 100 days. Therefore, while pre-emptive treat-
ment following a positive PCR assay appears to confer sur-
vival benefits, routine use in the clinical setting may present
challenges [39].
Barnes and colleagues reported on the reproducibility and
rapidity of PCR test results versus antigen testing by
performing assays for both Aspergillus and Candida . All cases
of proven disease were positive by both PCR and antigen
testing [79]. A comparison of the PCR and galactomannan
results revealed simultaneous positive results in six patients, a
positive PCR prior to galactomannan testing in 15 patients and
a positive galactomannan test prior to PCR in four patients [79].
HRCT
Most studies that reported use of HRCT were conducted in
oncology patients; few details were provided regarding rea-
sons for performing an HRCT scan (e.g. clinical suspicion or
as part of routine monitoring). Weisser and colleagues report-
ed on the use of HRCT scans in 161 episodes of infection in
107 patients with haematological malignancies [78]. Scans
were performed once weekly or when clinically indicated.
The halo sign, air crescent sign or cavitatory lesions were
classified as major signs from HRCT scans, whereas all other
infiltrates were classified as minor signs. Minor signs were
reported in 43 % of cases and major signs in 7 % of cases; no
infiltrate was seen with 50 % of the infection episodes.
Two studies reported the use of diagnostic HRCT scans in
populations other than oncology patients. In one study, a
suggestive HRCT was noted in 41 % of patients in a general
hospital who had a positive pulmonary isolate for Aspergillus
[63]. In the second study, which focused on critically ill
patients with neutropaenia, an HRCT scan was performed in
17/67 patients with probable or proven IAwith abnormalities
on chest X-ray. Of these, three patients had a halo sign and nine
had cavitation. The remaining five patients had non-specific
changes [17].
Early management approaches
Prophylaxis
The use of antifungal prophylaxis ranged from 28 to 100 %
in 21 identified studies across 12 countries. All azole- and
amphotericin-type products were used, and fluconazole was
the most frequently reported prophylactic agent. Most studies
did not address breakthrough infections, although a rate of
30 % was reported in an Austrian registry that defined
breakthrough infection as proven fungal infection after
7 days of prophylaxis [15]. Therapeutic drug monitoring
was not performed in this study; therefore, low drug
concentrations could not be excluded as the reason for
breakthrough infection.
Empirical therapy
Lafaurie and colleagues conducted a prospective chart review
of empirical therapy in a heterogeneous population of patients
admitted to haematology, oncology, ICU or infectious-disease
wards in a French hospital [31]. Empirical treatment was
initiated for refractory fever (39 %), recurrent fever (48 %),
clinical signs of sepsis (5 %) and tachycardia with elevated
C-reactive protein (CRP) (4 %) [31]. Caspofungin was the
first-line treatment in 71% of episodes, followed by liposomal
amphotericin B (18 %) and amphotericin B deoxycholate
(11 %) [31]. Eleven percent of patients had breakthrough
infection (any IFD identified after 3 days of empirical
treatment), although this could be attributed to the high-risk
population.
In a second study focusing on empirical therapy, a retro-
spective chart review of patients undergoing induction of
salvage chemotherapy for leukaemia given antifungal therapy
on day 4 of fever with negative cultures was conducted [57].
The fungal-attributable mortality was 2.5 %, leading the au-
thors to conclude that, while empirical therapy has become a
controversial treatment modality, it may be of value in selected
high-risk populations [57].
Pre-emptive therapy
Eight identified studies reported some form of a pre-emptive
strategy, although definitions were diverse. Criteria for treat-
ment initiation and the specific approaches used were different
for all pre-emptive studies (Table 1). The presence of clinical
signs and symptoms were triggers for treatment initiation in
two studies [28, 79]; HRCT scans alone or with clinical
microbiological or positive galactomannan tests triggered
treatment in five studies [17, 51, 74, 79, 82]; galactomannan
testing was used in four studies [17, 25, 51, 79], with one
study using the Candida mannan assay [79]; PCR testing was
used in two studies [39, 79]. A variety of treatment regimens
were given to patients. Seven studies pre-defined drug treat-
ment, while one study did not [51].
Overall, pre-emptive treatment was initiated in 7.7–51.7 %
of patients [17, 25, 39, 51, 74, 79, 82]. Most studies reported
pre-emptive antifungal use of between 39.2 and 51.7%. Three
studies reported low rates of pre-emptive treatment initiation
[17, 51, 82]. Maertens and colleagues had the lowest number
of patients receiving therapy due to strict requirements for
treatment initiation (two positive galactomannan assays or
positive microbiological results with suggestive CT findings)
[17]. Dignan and colleagues had strict definitions for antifun-
gal treatment initiation, which resulted in 17 % of patients
receiving pre-emptive treatment [82]. Caspofungin was
started: if there was a positive CT and neutropaenic fever; if
a CT could not be performed within 24 h; or at the discretion
of the physician in patients who developed respiratory failure
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with high dependency or were in the ICU [82]. In another
study, only one patient in the pre-emptive therapy arm received
treatment secondary to a negative IDWU and worsening
clinical condition [51].
These findings indicate a lack of consensus and under-
standing of the definition of pre-emptive therapy. Therefore,
the applicability of currently available data to the wider clin-
ical setting is unclear.
Empirical versus pre-emptive strategies
Ten studies across six countries reported on some form of
empirical or pre-emptive therapy. A summary of non-
randomised, observational studies of empirical and pre-
emptive treatments in adult patients is presented in Table 2.
Two prospective randomised studies conducted in oncology
patients directly compared empirical and pre-emptive strate-
gies (Table 3) [25, 39].
In the comparative studies, the incidence of IFDs ranged
between 2.7 and 8.2 % in empirically treated patients and
between 8.2 and 9.1 % in the pre-emptively treated patients
[25, 39]. In the study conducted by Cordonnier and colleagues,
the difference in the IFD rate between the treatment groupswas
statistically significant (pre-emptive 9.1 % vs. empirical 2.7 %,
p <0.02) [25]. The rate of IFDs was significantly higher in a
subgroup of patients who received induction therapy (16.4 %)
versus patients who received consolidation therapy/autologous
stem cell transplantation (3.9 %, p <0.01), with 15/17 IFD
cases occurring in the induction group and most infections
occurring in the pre-emptive arm (12 cases of IFD). Despite
the randomised study design, there were differences between
the two treatment groups, which must be taken into account
when interpreting these data. For example, greater morbidity
was recorded for patients in the pre-emptive group versus the
empirical group. Outcomes were similar between pre-emptive
and empirical strategies in the study by Hebart and colleagues,
where patient demographics were more consistent, all pa-
tients were on prophylaxis at baseline and only liposomal
amphotericin B was used [39].
The overall mortality in the two comparative trials ranged
from 1.5 to 16.5 % and IFDmortality ranged from 0 to 13.2 %
[25, 39]. The study by Cordonnier and colleagues demonstrat-
ed non-inferiority in the overall population between the em-
pirical and pre-emptive groups with regards to survival at
2 weeks after recovery from neutropaenia [25]. In a subgroup
analysis of patients who received induction therapy, the infe-
riority of pre-emptive versus empirical treatment in terms of
2-week survival could not be ruled out, but the study was not
powered to prove this. This may be related to a longer median
duration of neutropaenia in the pre-emptive versus the empir-
ical arm in patients receiving induction therapy (26 days vs.
12 days, respectively). By contrast, non-inferiority was dem-
onstrated for empirical versus pre-emptive treatment in a
subgroup of patients who received consolidation therapy/
autologous stem cell transplantation. While empirical treat-
ment may be comparatively beneficial versus pre-emptive
treatment in patients receiving induction therapy (but not in
patients receiving consolidation therapy), the differences be-
tween the groups in this study must be considered.
In the Hebart study, mortality at Day 100 did not differ
between the pre-emptive and empirical groups, although the
pre-emptive group had better survival at Day 30 [39]. Pre-
emptive treatment was initiated after a positive PCR test; after
Day 30, regular PCR testing became more difficult, as most
patients had been discharged from hospital. A study with
consistent PCR testing beyond 30 days would be instructive
in delineating whether pre-emptive treatment confers a tangi-
ble survival benefit over empirical therapy.
The studies reviewed herein indicated that IFD cases may
be missed less frequently when patients are treated pre-
Table 1 Diagnostic methods in pre-emptive treatment
Pre-emptive group criteria
Reference Country Clinical HRCT GM/M Microbiological PCR
Non-comparative studies
Maertens et al., 2005 [17] Belgium X X X
Girmenia et al., 2010 [51] Italy X X X
Posteraro et al., 2010 [56] Italy X
Aguilar-Guisado et al., 2010 [74] Spain X X X
Barnes et al., 2009 [79] UK X X X X X
Dignan et al., 2009 [82] UK X
Randomised, comparative studies
Cordonnier et al., 2009 [25] France X X X
Hebart et al., 2009 [39] Germany X
GM galactomannan, HRCT high-resolution computed tomography, M mannan, PCR polymerase chain reaction, UK United Kingdom
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emptively versus empirically. In total, seven IFD cases were
missed in three studies. Four proven cases of IFD were missed
in the empirical group and one proven case of IFD was missed
in the PCR-triggered pre-emptive group reported by Hebart
et al. [39]. Maertens and colleagues identified one case of
invasive zygomycosis where a patient in the empirical group
did not receive antifungal treatment [17]. This patient did
not present with fever or other signs of IFDs. By contrast,
ten patients were treated pre-emptively due to positive
galactomannan testing, despite being non-febrile or having
another source of fever identified. These patients had no
evidence of IFDs and would not have received treatment via
an empirical fever-driven strategy.
Cordonnier and colleagues defined breakthrough infec-
tions as infections documented ≥24 h after the first dose of
antifungal treatment. The occurrence of breakthrough infec-
tions was similar for the empirical and pre-emptive treatment
arms (empirical arm Aspergillus infections, 1.3 % of patients;
pre-emptive arm Aspergillus species or Candida species,
1.4 % of patients for both organisms) [25]. Two cases of
breakthrough candidaemia with C . glabrata were identified
with blood cultures in a study of pre-emptive treatment by
Maertens and colleagues [17].
Overall, excluding the study byHebart et al. [39], empirical or
potentially empirical antifungal use ranged from 35 to 61.3 %,
while pre-emptive antifungal use ranged from 7.7 to 39.4 %.
Thus, five out of six studies demonstrated an overall decrease in
antifungal use by 43–78 % with the use of a pre-emptive
treatment versus empirical strategy [17, 25, 51, 74, 79, 82].
Limited data are available comparing the cost-effectiveness
of pre-emptive versus empirical strategies for IFDs. However,
a benefit in terms of cost and LOS in high-risk patients has
been suggested for pre-emptive treatment [79].
These results emphasise the diverse diagnostic methods
and therapeutic modalities that can be used within a pre-
emptive strategy. Various IFDs were represented in the stud-
ies, including Candida species. However, when patient pop-
ulations were consistent, all patients received prophylaxis at
baseline and amphotericin B was used by all patients, and
outcomes were similar for pre-emptive and empirical treat-
ment strategies [39]. The rates of breakthrough infection were
comparable. The rates of antifungal use were lower with pre-
emptive treatment and infection may be detected more fre-
quently using this strategy. Additional studies of pre-emptive
antifungal treatment are warranted.
Economic burden of IFDs
Fifteen studies across eight countries reported economic or
HCRU data; these studies reported greater costs in patients
with IFDs versus patients without infection. In an observa-
tional study in patients with acute myelogenous leukaemia
(AML)–myelodysplastic syndromes (MDS) receiving high-
dose chemotherapy, the mean total cost per patient was
€57,750 with no IA, €68,280 with possible IA and €83,300
with probable or proven IA [61]. The additional IA cost
burden ranged from €10,530 to €25,550, and was statistically
significantly greater across all areas of expenditure in patients
with possible, probable or proven IA versus patients without
IA (p <0.001) [61]. A longer LOS was noted for patients with
possible IA (91 days) and probable or proven IA (104 days)
versus patients without IA (84 days) [61].
Gangneux and colleagues reported on 50 patients with AML
with probable or proven IFD followed for 1 year [29]. LOS for
index hospitalisation was 45 days (82 % of stays were for
malignancy treatment) and the mean duration of antifungal
treatment was 198 days [29]. The increase in treatment costs
for an IFD episode was €51,033; antifungals accounted for
€35,967 (70.5 %) of this expenditure during the year [29]. The
cost of index hospitalisation was €13,721, plus €1,345 for each
additional hospitalisation [29]. Berger and colleagues reported
on the burden of IFDs in patients who had undergone remis-
sion induction chemotherapy for AML or MDS and included
those with proven or probable IFD receiving antifungal treat-
ment [35]. Overall, patients with IFDs stayed in hospital
12 days longer than patients without IFDs [35].
The economic impact of IFDs can be assessed from the
hospital, payer or societal perspectives. Although the hospital
perspective includes only costs that are incurred by the hospital
(e.g. costs of diagnostic tests, medications, hospitalisation), the
payer perspective includes all direct medical costs (e.g. prima-
ry treatment costs, costs of HCRU post-discharge) and the
societal perspective includes all direct medical and non-
medical costs (e.g. lost productivity), as well as indirect costs
(e.g. future lost productivity).
Hospital perspective
The hospital perspective costs varied depending on the re-
sources included in the analysis. Costs generally ranged from
€8,351 to €11,821 when evaluating incremental hospitalisation
and antifungal drug expenditure only, €3,930–€7,314 for anti-
fungal drugs, €8,252–€51,760 for hospital bed day costs and
€26,596–€83,300 when all direct costs for management were
included [35–37, 58, 59, 61, 67, 68, 77, 86].
Payer perspective
Bruynesteyn and colleagues used a decision tree to compare
the cost-effectiveness of caspofungin versus liposomal
amphotericin B from the UK National Health Service perspec-
tive [80]. The average direct treatment costs were £9,763 for
caspofungin and £11,795 for liposomal amphotericin B, where
the drug costs were £4,601 and £6,395, respectively [80]. The
difference in other direct costs, including hospitalisation and
drug costs related to the management of adverse events, was
16 Eur J Clin Microbiol Infect Dis (2014) 33:7–21
£239 in favour of caspofungin up to a weight of 77 kg [80].
Van Campenhout and colleagues compared cost data from an
observational study with a model utilising voriconazole for IA
therapy [19]. The average total costs of treatment when con-
sidering only hospital days associated with fungal infection
was €12,376, and most of this was associated with antifungal
use [19].
Societal perspective
Two studies reported costs from the societal perspective,
although one study reported a narrow societal perspective
and only included direct costs [40, 60]. Both studies used a
Markov model and compared voriconazole with conventional
amphotericin B for IA, with one study also including
itraconazole [40, 60]. The mean treatment costs for
voriconazole and conventional amphotericin B ranged from
€25,353 to €26,974 in a 12-weekmodel and €30,026–€33,616
in a life-long model [40, 60].
Summary and discussion
Despite the availability of a range of therapeutic options, the
clinical and economic burden of IFDs remains high.
Considerable variation in reporting methods for IFD-related
mortality data was observed, making interpretation difficult. In
many cases, denominator data were not included and attribut-
able mortality could not be differentiated from crude mortality.
Some studies may have been affected by ascertainment bias
[17, 25, 63, 78]. The inclusion of some biomarkers (e.g.
galactomannan, β-D-glucan) and not others (e.g. PCR), and
the heavy reliance on specific radiological signs in EORTC/
MSG criteria, has led to a stricter definition of IFD, resulting in
a significant reduction of possible/probable IFD cases, with an
anticipated improvement in specificity for clinical trials [2],
However, the criteria are unsuitable for the evaluation of new
diagnostic tools because existing criteria are used to define the
disease, which may lead to ascertainment bias.
Guidelines provide recommendations for the use of biologi-
cal tests in adult patients [91, 92]. Although strong evidence
supports the use of galactomannan testing in serum, only mod-
erate evidence supports the use of combined mannan/anti-
mannan testing in serum [91]. Anti-mannan antibody testing
was not included in this analysis. No PCR recommendations
were proposed, owing to a lack of standardisation [91]. HRCT
scans and the galactomannan assay were used for diagnosis,
although cut-offs and the frequency of testing varied. Utilisation
of the (1,3)-β-d-glucan assay and PCR testing was limited.
Avariety of termswere used to describe strategies for the
prevention and treatment of IFD, leading to confusion
and overlap. Antifungal prophylaxis was used in many
studies, but the definition of efficacy or failure varied.
Empirical treatment was generally defined as the initiation of
antifungal therapy in a neutropaenic patient with persistent
fever, despite broad-spectrum antibiotics for 4 to 7 days.
Other terms included universal empirical and early an-
tifungal therapy. Several studies misinterpreted pre-emptive
therapy, a strategy which aims to detect infection before
clinical disease develops. When clinical and radiological dis-
ease is present, the opportunity for the pre-emptive therapy
of infection has passed. Other terms identified included
clinically driven, diagnostic-driven treatment and targeted
prophylaxis/therapy.
Although there is a dearth of studies comparing empirical
and pre-emptive treatment strategies, only two randomised,
controlled studies were identified. The variations in diagnosis
and treatment in these studies led to difficulties in developing
conclusions regarding the role of pre-emptive therapy. A
prospective, randomised clinical study comparing empirical
and diagnostic-driven (pre-emptive) therapy in patients with
acute leukaemia or undergoing allogeneic SCT is ongoing in
European centres (NCT01288378).
Studies assessing the economic burden of IFDs are limited;
the incremental cost burden is estimated to be between €10,530
and €51,033, depending on the certainty of infection and the
duration of follow-up. Drivers of HCRU burden included
hospitalisation, diagnostic testing and medications. To demon-
strate a clear cost benefit, further evidence that a pre-emptive
strategy decreases antifungal use compared with a standard
empirical approach is needed.
In conclusion, the primary evidence reported here demon-
strates the importance of IFDs in Europe and highlights the
need for early and appropriate therapy, facilitated by new
techniques for more rapid diagnosis. Additional studies are
required in order to establish the clinical and economic burden
of IFDs, and assess current treatment practices.
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